Madhu Sharma, Naresh Mittapelly, Venkatesh Teja Banala, Sandeep Urandur, Shalini Gautam, Disha Marwaha, Nikhil Rai, Neha Singh, Ashutosh Gupta, Kalyan Mitra, Prabhat Ranjan Mishra
HR+/HER2- metastatic breast cancer (MBC) is one of the most common and life-threatening conditions diagnosed in women. The endocrine therapy using an orally active CDK4/6 inhibitor, ribociclib (RB), is the most intriguing approach for treating HR+/HER2- MBC. However, the repeated three to six cycles of multiple dosing and non-targeted distribution of RB led to severe neutropenia; hepatobiliary, gastrointestinal, and renal toxicities, and QT interval prolongation. Here, a novel organic solvent-free HA-PVA-PVP (hyaluronic acid-polyvinyl alcohol-polyvinyl pyrrolidone) composed of a microneedle (MN) array is formulated to deliver RB, integrated with amphiphilic conjugated polymer (HA-GMS)-anchored ultradeformable transfersomes...
March 14, 2022: Biomacromolecules